A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples